This inventor holds 1 USPTO granted patent and 3 published patent applications and 2 EPO patents. Top assignee: University of Michigan. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: Innovations of Chenxi Shen in the Field of Leukemia Research.
Introduction
Chenxi Shen is an accomplished inventor based in Beijing, China. He has made significant contributions to the field of leukemia research through his innovative patents. His work focuses on the mechanisms of MLL fusion proteins and their role in activating target genes.
Latest Patents
Chenxi Shen holds a patent titled "Compositions and methods relating to hindering DOT1L recruitment by MLL-fusion proteins." This invention addresses the recruitment of histone methyltransferase DOT1L by MLL fusion proteins, such as AF9 and ENL. The patent provides insights into the AF9/ENL binding site in DOT1L and introduces agents that block the protein-protein interactions between AF9/ENL and DOT1L. This innovation aims to inhibit the activity of DOT1L and, consequently, the leukemia associated with MLL-fusion proteins. He has 1 patent to his name.
Career Highlights
Throughout his career, Chenxi Shen has worked with prestigious institutions, including the University of Michigan and Hengtong Optic-Electric Co., Ltd. His experience in these organizations has enriched his research and development capabilities.
Collaborations
Chenxi has collaborated with notable professionals in his field, including Zaneta Nikolovska-Coleska and Jay L Hess. These collaborations have further advanced his research and contributed to the scientific community.
Conclusion
Chenxi Shen's innovative work in leukemia research exemplifies the impact of targeted therapies in medicine. His contributions through patents and collaborations continue to pave the way for advancements in cancer treatment.